• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novocure misses sales, earnings estimates in Q2

July 27, 2017 By Sarah Faulkner

NovocureShares in Novocure (NSDQ:NVCR) fell today after the oncology company missed expectations on Wall Street with its second quarter results.

The St. Helier, N.J.-based company reeled in its losses to -$21.2 million on sales of $38.4 million for the 3 months ended June 30, for bottom-line growth of 48% on sales growth of 114% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were -24¢, behind consensus on The Street, where analysts were looking for sales of $40.4 million.

“The second quarter of 2017 was a period of steady growth across all key commercial metrics in all key markets. At the end of the quarter, we had 1,460 active patients on therapy,” CEO Asaf Danziger said in prepared remarks. “We believe second quarter growth benefitted from our ongoing emphasis on building prescriber confidence in Optune for the treatment of GBM, including the presentation of our EF-14 five-year survival data at AACR.”

“With 204 million U.S. lives under positive coverage polices as of June 30, 2017, more than 93% of Americans with private insurance now have access to Optune,” Danziger added. “We continue to be reimbursed on a case-by-case basis in Germany and are in a constructive dialogue with government payers in the United States, Switzerland and Japan. Our second quarter 2017 revenues of $38.4 million represent 114 percent growth versus the second quarter 2016.”

NVCR shares were trading at $18.10 apiece today in morning activity, down -5.9%.

Earlier this week, the company announced it would collaborate with Celgene (NSDQ:CELG) to study an investigational drug in combination with its Optune “tumor-treating fields” device. The Phase Ib trial is slated to evaluate the drug-device combination in patients with newly-diagnosed glioblastoma.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Oncology, Wall Street Beat Tagged With: Celgene, NovoCure

IN CASE YOU MISSED IT

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Glucotrack can proceed with long-term glucose monitor study in Australia
  • Dexcom promotes Jake Leach to president role
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS